Replimune Group, Inc. (REPL) Balance Sheet

The downward trajectory is primarily fueled by the expansion of retained earnings losses, which deepened from -$701.3M to -$1.3B over the period, consuming shareholder equity faster than new capital is raised. This consistent depletion of the equity cushion, rather than asset growth or debt accumulation, is the defining feature of the company's balance sheet evolution, signaling a business consuming its resources to fund pre-commercial operations.

The sharp rise in leverage, particularly the near-doubling of debt in the last two quarters, suggests management is accessing credit facilities to extend its operational runway without immediate equity dilution. This shift is notable given the company remains pre-revenue; the willingness to service debt from a cash balance that has peaked and is now declining to $185.4M implies confidence in upcoming milestones or a calculated risk to avoid severe shareholder dilution in the near term.

While a current ratio above 5 remains nominally strong, the rapid pace of its decline—halving in just over a year—reflects the accelerating cash burn rate identified in the cash flow statements. The narrowing gap between current assets and liabilities, coupled with a debt load that now equals over 100% of equity, suggests the company's financial flexibility is increasingly constrained, leaving it more vulnerable to any delays in clinical progress or capital markets access.

The absence of any treasury stock or significant equity issuances in recent quarters points to a period where the company is funding itself through debt and existing cash, rather than dilutive offerings. However, the precipitous decline in equity heightens the risk of future dilution; a modest capital raise would now have a disproportionately larger impact on ownership percentages, as the equity cushion provides a much smaller base against which new shares would be issued.